Literature DB >> 2249324

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

S Lundgren1, P E Lønning, A Aakvaag, S Kvinnsland.   

Abstract

In this study the influence of amino-glutethimide (AG) on the disposition of medroxyprogesterone acetate (MPA) and megestrol acetate (MA) was studied. When 1,000 mg AG daily was supplementally given to six patients on chronic treatment with MPA (1,000 mg/day) or MA (160 mg/day), mean serum levels of progestin were reduced by 74% as compared with control levels (P less than 0.03). AG did not change the blood clearance rate of MPA when the latter was given i.v. This discrepancy between AG's influence on oral and parenteral progestin disposition could be explained by pharmacokinetic properties of the progestins, and our results suggest that AG stimulates the metabolism of progestins. The decrease in MPA and MA serum levels was accompanied by an increase in serum cortisol, sex hormone-binding globulin (SHBG) and testosterone levels. This suggests that AG reduces the biological activity of progestins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249324     DOI: 10.1007/bf00689091

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  Oral high-dose progestins as treatment for advanced breast cancer.

Authors:  S Lundgren; S Kvinnsland; E Utaaker
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

2.  [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].

Authors:  H E Wander; U R Kleeberg; E Gärtner; J Hartlapp; A Scherpe; E Bönisch; G A Nagel
Journal:  Onkologie       Date:  1987-04

3.  High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.

Authors:  C J Gallagher; F Cairnduff; I E Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1987-12

4.  A radioimmunoassay for serum medroxyprogesterone acetate.

Authors:  K Shrimanker; B N Saxena; K Fotherby
Journal:  J Steroid Biochem       Date:  1978-04       Impact factor: 4.292

5.  Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.

Authors:  L R Morgan
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

6.  The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione) in women.

Authors:  J M Cooper; A E Kellie
Journal:  Steroids       Date:  1968-02       Impact factor: 2.668

7.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.

Authors:  C Gupta; J Osterman; R Santen; C W Bardin
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

9.  Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.

Authors:  H van Veelen; P H Willemse; T Tjabbes; M J Schweitzer; D T Sleijfer
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

10.  Megestrol acetate versus aminoglutethimide for metastatic breast cancer.

Authors:  S Lundgren; S Gundersen; R Klepp; P E Lønning; E Lund; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1989-11       Impact factor: 4.872

View more
  5 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 4.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

5.  Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.

Authors:  F A MacNeill; S Jacobs; P E Lønning; T J Powles; M Dowsett
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.